Clinical Report: Effectiveness of Apremilast in Psoriasis with Minimal Involvement

Overview

This pooled analysis of six clinical trials demonstrates that apremilast significantly improves skin clearance and quality of life in patients with plaque psoriasis exhibiting minimal skin involvement (3-10% BSA), particularly in high-impact anatomical sites.

Background

Plaque psoriasis can severely affect quality of life, even with limited skin involvement. High-impact sites, such as the scalp and genital area, are particularly burdensome, yet systemic treatment options for these patients are limited. The 2020 International Psoriasis Council guidelines recommend systemic therapy for those with high-impact site involvement.

Data Highlights

Key Findings

• Apremilast improved skin clearance in patients with 3-10% BSA involvement.
• Quality of life enhancements were noted at both weeks 16 and 32.
• Benefits were sustained through week 32 for patients with high-impact site involvement.
• Clinical trials included ADVANCE, DISCREET, STYLE, EMBRACE, UNVEIL, and PROMINENT.

Clinical Implications

Clinicians should consider apremilast for patients with limited plaque psoriasis, especially those affected in high-impact areas.

Conclusion

The findings support the use of apremilast as an effective treatment for patients with plaque psoriasis and limited skin involvement, particularly in high-impact areas.

Related Resources & Content

1. MDSpire News, 2023 -- Apremilast Shows Promise in Early Oligoarticular PsA
2. Dermatology and Therapy, 2023 -- Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
3. Drug Safety, 2022 -- Evaluation of Apremilast Safety in Individuals with Psoriasis and Psoriatic Arthritis: Insights from the UK Clinical Practice Research Datalink
4. International Psoriasis Council, 2025 -- psoriasis disease severity reclassification: Update on validity, acceptance, and implementation
5. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring - PMC
6. ACR Open Rheumatology — Evaluating the Effectiveness and Safety of Combined Targeted Therapy for Refractory Psoriatic Arthritis: Insights from a Prospective Cohort Study
7. International Psoriasis Council psoriasis disease severity reclassification: Update on validity, acceptance, and implementation
8. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 1: Treatment recommendations and monitoring - PMC
9. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial - PubMed
10. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study - PMC
11. Apremilast: Real-life efficacy and safety in psoriasis limited to the nails - ScienceDirect
12. Systematic review and network meta‐analysis of biologics and small molecules for scalp psoriasis - Lai - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library